Abstract
Sorafenib prolongs survival of patients with unresectablehepatocellular carcinoma (HCC). It is likely to be used in human immunodeficiency virus (HIV) infected patients. Interactions between sorafenib and highly active antiretroviral therapy (HAART) have not been studied yet. We report a case of serious adverse effects in anHIV-1 patient co-infected with HBV.
MeSH terms
-
Antiretroviral Therapy, Highly Active / adverse effects*
-
Benzenesulfonates / adverse effects*
-
Carcinoma, Hepatocellular / drug therapy*
-
Carcinoma, Hepatocellular / virology
-
Drug Interactions
-
HIV-1*
-
Hepatitis B, Chronic / complications
-
Hepatitis C, Chronic / complications
-
Humans
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / virology
-
Male
-
Middle Aged
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Protein Kinase Inhibitors / adverse effects*
-
Pyridines / adverse effects*
-
Sorafenib
Substances
-
Benzenesulfonates
-
Phenylurea Compounds
-
Protein Kinase Inhibitors
-
Pyridines
-
Niacinamide
-
Sorafenib